Source Radar — reputable sources, queries & discovery method

Source Radar — targets & method

Drives Schedule 1 (Research Radar). Goal: catch new peptide-relevant evidence fast — new human trials, oncology/metabolic findings, approvals, major reviews — and record them as kb-source notes threaded into the graph.

Reputability bar (a source must clear this to be recorded)

Peer-reviewed journal, named authors with institutional affiliation, a registered trial, or a recognised conference/oncology network reporting same. Tier honestly in the note: literature (journal/trial) > clinical-observational > conference > educational (named-expert explainer) > anecdote (forum/marketing — usually skip).

Standing sources to check each run

• PubMed — newest results for our priority compounds (filter to recent).
• ClinicalTrials.gov — new/updated peptide trials & results.
• ASCO / The ASCO Post / Oncology Central — oncology + GLP-1/metabolic-peptide signals (the seed source: https://www.oncology-central.com/).
• High-impact journals for peptides/metabolism: JAMA Network Open, NEJM, Cell Metabolism, Nature Reviews Endocrinology, Br J Pharmacol, Bull Exp Biol Med (Khavinson/Russian peptide work).
• Examine.com — evidence summaries (good for corroboration).
• Named physician/educator outputs — Koniver, Attia, Huberman Lab (educational tier; for protocols/angles, not as primary evidence).
• Sponsor pivotal-trial topline releases — e.g. Eli Lilly / Novo Nordisk investor newsrooms (added 2026-06-15). High-signal for Phase 3 readouts before peer-reviewed publication, but always corroborate with ≥2 independent medical outlets and label “topline tier” — never record on a press release alone.
• Diabetes, Obesity and Metabolism (Wiley) — added 2026-06-15; peer-reviewed home for GLP-class trial design/readout papers (e.g. TRIUMPH design paper).
• Reputable trial-news corroborators — Healio, AJMC, TCTMD, Pharmacy Times, Fierce Biotech/Pharma (added 2026-06-15; corroboration tier, not primary).
• ADA Scientific Sessions — added 2026-07-01; the annual diabetes/metabolic conference and the primary venue where GLP-class Phase 3 obesity/metabolic readouts land (e.g. survodutide SYNCHRONIZE-1/-MASLD, 2026). Conference tier; pairs with simultaneous NEJM/Nature Medicine publication.
• JCO Oncology Practice (ASCO journal) & Nature Medicine — added 2026-07-01; peer-reviewed homes for, respectively, ASCO real-world/oncology-practice analyses (GLP-1 breast-cancer incidence) and high-impact obesity Phase 3 co-publications (survodutide). Literature tier.
• FDA Advisory Committee Calendar + Federal Register / Regulations.gov dockets — added 2026-07-01; the PRIMARY source for US peptide regulatory events (PCAC 503A bulk-list reviews, Category-1/2 changes, FDA briefing documents). Label “regulatory” tier — NOT efficacy evidence; corroborate interpretation with National Law Review, Lengea Law, BSCG, Pharmacy Times. Watch this for anything touching catalog peptides (BPC-157/TB-500/MOTS-c/KPV/DSIP/Semax/Epitalon/GHK-Cu/Melanotan II).

Standing search queries (run with a recency filter)

• “BPC-157 human clinical trial” / “BPC-157 randomized”
• “TB-500 / thymosin beta-4 clinical trial”
• “GLP-1 receptor agonist cancer” / “semaglutide tirzepatide retatrutide outcomes 2026”
• “tesamorelin trial” / “growth hormone secretagogue trial”
• “MOTS-c human study” / “mitochondrial peptide SS-31 elamipretide trial”
• “epitalon / pineal peptide telomere clinical”
• “new peptide therapeutic approval 2026”
• One query per priority peptide we sell, ”+ trial OR study 2026”.

Discovery method (grow the list every run)

1. From each strong new finding, harvest its journal, authors, and citing/cited works → add recurring high-quality venues/authors to this file.
2. Follow citation networks: a new BPC-157 trial → check the group’s other work and who cites it.
3. Track conferences (ASCO, ENDO, ADA) for peptide-adjacent abstracts.
4. Add any new outlet that clears the reputability bar; note why it qualifies.

Output per run

• New kb-source note in Sources/ per finding (frontmatter: type kb-source, id SOURCE-…, title, publisher, url, provenance, evidence, captured date, linked peptides/mechanisms, research_use_only, tags) + a short “Key findings / Why it matters / Caveats / Corroboration” body.
• Thread the finding into the relevant Peptides/ and Mechanisms/ notes (add to sources: and a one-line note in the body).
• Append article ideas to Article Backlog.md (P0 for breakthroughs).
• Update “Last run” + new sources discovered, below.
• Digest to the user: what’s new, impact, what was enqueued.

Log

• Last run: 2026-07-01 — 4 new kb-source notes recorded. Highest-impact: FDA PCAC 503A peptide review (July 23–24 2026) — the agency will vote on adding BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax & Epitalon to the §503A compounding bulk-list; anchored on the FDA.gov advisory-committee page (7 briefing PDFs + docket FDA-2025-N-6895) and the Feb-2026 HHS Category-2 removal of ~12 peptides. Also recorded: GLP-1 → lower breast-cancer INCIDENCE (ASCO 2026 Abstract 10506 / JCO Oncology Practice — a new prevention axis distinct from the two existing progression/outcomes notes), the first registered human RCT of MOTS-c (NCT07505745, Phase 2a prediabetes, recruiting), and survodutide SYNCHRONIZE-1 Phase 3 (16.6% weight loss, liver fat −63%; ADA 2026 / NEJM + Nature Medicine). Retatrutide TRIUMPH-2/-3 still pending (fast-lane P1 remains queued). SS-31/elamipretide Barth approval already captured (skipped). ClinicalTrials.gov pages JS-rendered → relied on registry-confirmed snippets + corroboration; FDA.gov + ASCO Post fetched cleanly (no workaround used). Notably resolved the July-23-2026 PCAC claim that the does-tb-500-have-human-trials article had flagged as uncorroborated.
  • Newly discovered sources (this run):
    • SOURCE-fda-pcac-503a-peptide-review-2026 — FDA PCAC 503A vote on 7 peptides (regulatory tier).
    • SOURCE-glp1-breast-cancer-incidence-mcdonald-2026 — GLP-1 RA → lower breast-cancer incidence (ASCO 2026 / JCO OP; clinical-observational).
    • SOURCE-motsc-prediabetes-phase2a-nct07505745 — first registered human MOTS-c RCT (recruiting).
    • SOURCE-survodutide-synchronize1-phase3-2026 — survodutide Phase 3 obesity readout (ADA 2026; NEJM + Nature Medicine).
  • New venues added to the standing list (this run): ADA Scientific Sessions; JCO Oncology Practice; Nature Medicine; FDA Advisory Committee Calendar + Federal Register/Regulations.gov dockets (regulatory tier).
• Last run: 2026-06-15 — 3 new kb-source notes recorded; 1 existing GLP-1/cancer note extended with 2026 corroboration. Highest-impact: Retatrutide TRIUMPH-1 Phase 3 (up to 28.3% weight loss). SS-31 Barth-syndrome approval checked but already captured in the SS-31 note (skipped, no duplicate). ClinicalTrials.gov + Lilly pages were JS-rendered/empty → relied on search snippets + multi-outlet corroboration (per rules; no fetch workaround used).
• Newly discovered sources (this run):
  • SOURCE-retatrutide-triumph1-phase3 — Retatrutide TRIUMPH-1/-4 Phase 3 (Lilly topline + 5 corroborators).
  • SOURCE-bpc157-hamstring-rct-nct07437547 — first registered BPC-157 RCT (acute hamstring strain; recruiting).
  • SOURCE-tb500-ascvd-rct-nct07487363 — first registered TB-500 (TB4 17–23) human trial (Phase 1/2, stable ASCVD).
• New venues added to the standing list (this run): sponsor pivotal-trial topline releases (corroborate-before-recording rule), Diabetes Obesity & Metabolism, and reputable trial-news corroborators (Healio/AJMC/TCTMD/Pharmacy Times/Fierce).